Thrombate III Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The thrombate III market research report is one of a series of new reports that provides thrombate III market statistics, including the thrombate III industry global market size, regional shares, competitors with the thrombate III market share, detailed thrombate III market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombate III industry. This thrombate III market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing geriatric population, growing incidence of bleeding, expansion of healthcare infrastructure, rising demand for personalized medicine, and growing incidence of genetic disorders. Major trends in the forecast period include the integration of advanced biotechnology, the development of novel therapeutic formulations, the adoption of digital healthcare solutions, increased research and development activities, and regulatory improvements in drug approvals.

The increasing prevalence of hemophilia is expected to significantly contribute to the growth of the thrombate III market in the future. Hemophilia is a rare genetic disorder characterized by improper blood clotting due to a deficiency in essential clotting factors, leading to prolonged bleeding after injuries, surgeries, or even spontaneous bleeding into joints or muscles. The rise in hemophilia cases is linked to factors such as genetic mutations, family history, and advancements in diagnostic methods, which have led to improved detection and reporting of the condition. Thrombate III is used in the treatment of hemophilia to control bleeding by providing activated antithrombin III, which inhibits clotting factors and helps prevent excessive bleeding. For example, in October 2023, the World Federation of Hemophilia, a Canada-based non-profit organization, reported that in 2022, approximately 427,685 individuals worldwide were diagnosed with bleeding disorders, including 257,146 cases of hemophilia. This growing prevalence of hemophilia is expected to drive the demand for thrombate III.

The rise in healthcare infrastructure is also expected to propel the growth of the thrombate III market. Healthcare infrastructure refers to the physical facilities, workforce, systems, and resources necessary to deliver effective and accessible healthcare services. As populations age and medical technology continues to advance, there is a greater need for healthcare facilities and innovative treatments. The development of healthcare infrastructure enhances access to specialized treatments, diagnostic facilities, and skilled healthcare professionals, which is crucial for managing conditions such as antithrombin III deficiency. For instance, in May 2023, the American Health Care Association reported that the number of hospitals in the United States increased by 0.591%, from 6,093 in the previous year to 6,129 in 2023. This growing healthcare infrastructure supports the increasing demand for thrombate III.

The growth in the number of surgical procedures is another factor expected to drive the expansion of the thrombate III market. Surgical procedures refer to medical operations or interventions performed by healthcare professionals to treat or diagnose various conditions, often involving incisions to treat internal areas of the body. The rise in surgical procedures can be attributed to factors such as advancements in medical technology, an aging population, the growing prevalence of chronic diseases, and better healthcare access. Thrombate III plays a vital role in preventing excessive blood clotting during surgeries, particularly for patients with antithrombin III deficiency, thus reducing the risk of complications such as deep vein thrombosis or pulmonary embolism. For example, in September 2023, the International Society of Aesthetic Plastic Surgery reported a 11.2% increase in the number of surgical procedures performed in 2022 compared to the previous year, with over 14.9 million surgeries and 18.8 million non-surgical procedures globally. The growing number of surgical procedures is expected to further fuel the demand for thrombate III.

The key company operating in the thrombate III market is Grifols S.A.

North America was the largest region in the thrombate III market in 2024. The regions covered in thrombate III report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombate III market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Thrombate III (generic name: antithrombin III [human]) is a prescription medication used to treat or prevent blood clotting disorders in individuals with antithrombin III deficiency. It is primarily prescribed to patients with hereditary antithrombin III deficiency to prevent the formation of blood clots, particularly in high-risk situations such as surgery or childbirth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for thrombate III include surgical procedures and hereditary antithrombin deficiency. Surgical procedures refer to medical operations performed by skilled surgeons to address or manage diseases, injuries, or conditions, often involving incisions or modifications to the body. The medication is distributed through various channels, including hospital pharmacies and online pharmacies, and is used by a range of end users, including adults and elderly patients.

The thrombate III market consists of sales of vials, pre-filled syringes, reconstitution kits, administration kits, and storage and transport kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.